Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 agonist, which Lilly renamed mazisotine, recently came through a phase 2 ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH By Nick Paul Taylor Feb 10, 2025 9:40am Eli Lilly MASH radiopharmaceuticals Licensing deals ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly and Co. officially opened its new Lilly Seaport Innovation Center on Tuesday. Gary Higgins / Boston Business Journal 1 of 11 By Hannah Green – Reporter, Boston Business Journal Aug 13 ...

Eli Lilly officials and Gov. Mike Braun break ground on the LEAP District's Lilly Medicine Foundry, a $4.5 billion project creating 400 jobs.

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products for Human Use (CHMP) has ...

Shares of Eli Lilly (LLY 0.55%) and Novo Nordisk (NVO 2.80%) have been climbing steadily over the past 30 days, with the former gaining 19% and the latter rising by 12%.